RT Journal Article
SR Electronic
T1 Comparative analysis of the outcomes of COVID-19 between patients infected with SARS-CoV-2 Omicron and Delta variants: a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.30.22274532
DO 10.1101/2022.04.30.22274532
A1 Gunadi,
A1 Hakim, Mohamad Saifudin
A1 Wibawa, Hendra
A1 Vujira, Khanza Adzkia
A1 Puspitarani, Dyah Ayu
A1 Supriyati, Endah
A1 Trisnawati, Ika
A1 Iskandar, Kristy
A1 Khair, Riat El
A1 Afiahayati,
A1 Siswanto,
A1 Puspadewi, Yunika
A1 Irene,
A1 Irianingsih, Sri Handayani
A1 Daniwijaya, Edwin Widyanto
A1 Agung Nugrahaningsih, Dwi Aris
A1 Gabriela, Gita Christy
A1 Geometri, Esensi Tarian
A1 Eryvinka, Laudria Stella
A1 Trie Utami, Fadila Dyah
A1 Devana, Edita Mayda
A1 Aditama, Lanang
A1 Putri Kinasih, Nathania Christi
A1 Amadeus, Verrell Christopher
A1 Hediningsih, Yekti
A1 Ananda, Nur Rahmi
A1 Arguni, Eggi
A1 Nuryastuti, Titik
A1 Wibawa, Tri
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/05/03/2022.04.30.22274532.abstract
AB Background The SARS-CoV-2 Omicron variant has replaced the previously dominant Delta variant because of high transmissibility. It is responsible for the current increase in the COVID-19 infectivity rate worldwide. However, studies on the impact of the Omicron variant on the severity of COVID-19 are still limited in developing countries. Here, we compared the outcomes of patients infected with SARS-CoV-2 Omicron and Delta variants and associated with prognostic factors, including age, sex, comorbidities, and smoking.Methods We involved 352 patients, 139 with the Omicron variant and 213 with the Delta variant. The whole-genome sequences of SARS-CoV-2 were conducted using the Illumina MiSeq next-generation sequencer.Results Ct value and mean age of COVID-19 patients were not significantly different between both groups (Delta: 20.35 ± 4.07 vs. Omicron: 20.62 ± 3.75; p=0.540; and Delta: 36.52 ± 21.24 vs. Omicron: 39.10 ± 21.24; p=0.266, respectively). Patients infected with Omicron and Delta variants showed similar hospitalization (p=0.433) and mortality rates (p=0.565). Multivariate analysis showed that older age (≥65 years) had higher risk for hospitalization (OR=3.67 [95% CI=1.22-10.94]; p=0.019) and fatalities (OR=3.93 [95% CI=1.35-11.42]; p=0.012). In addition, patients with cardiovascular disease had higher risk for hospitalization (OR=5.27 [95% CI=1.07-25.97]; p=0.041), whereas patients with diabetes revealed higher risk for fatalities (OR=9.39 [95% CI=3.30-26.72]; p=<0.001).Conclusions Our study shows that patients infected with Omicron and Delta variants reveal similar clinical outcomes, including hospitalization and mortality. In addition, our findings further confirm that older age, cardiovascular disease, and diabetes are strong prognostic factors for the outcomes of COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Indonesian Ministry of Health and Dr. Sardjito Hospital funded our study. The funders had no role in study design, data collection, and analysis, decision to publish, or manuscript preparation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Medical and Health Research Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia (KE/FK/0563/EC/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://www.gisaid.org/